id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0248-0003,FDA,FDA-2022-E-0248,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:43:52Z,,0,0,09000064852ceb12
FDA-2022-E-0248-0001,FDA,FDA-2022-E-0248,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T20:53:01Z,,0,0,0900006484fadffc
FDA-2022-E-0248-0002,FDA,FDA-2022-E-0248,Patent Extension Application from Casimir Jones S.C. (on behalf of ADC Therapeutics S.A. (ADCT),Other,Application,2022-02-28T05:00:00Z,2022,2,2022-02-28T05:00:00Z,,2022-02-28T20:53:05Z,,0,0,0900006484fae011